Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Diagnostics & Testing
- Sub-Industry: N/A
- Symbol: NASDAQ:IOVA
- CUSIP: N/A
- Web: www.iovance.com
- Market Cap: $482.69 million
- Outstanding Shares: 62,687,000
- 50 Day Moving Avg: $5.61
- 200 Day Moving Avg: $6.42
- 52 Week Range: $4.45 - $8.61
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.24
- P/E Growth: 0.00
- Return on Equity: -18.59%
- Return on Assets: -17.95%
- Current Ratio: 15.29%
- Quick Ratio: 15.29%
- Average Volume: 360,975 shs.
- Beta: 4.5
Frequently Asked Questions for Lion Biotechnologies (NASDAQ:IOVA)
What is Lion Biotechnologies' stock symbol?
Lion Biotechnologies trades on the NASDAQ under the ticker symbol "IOVA."
How were Lion Biotechnologies' earnings last quarter?
Lion Biotechnologies, Inc. (NASDAQ:IOVA) announced its earnings results on Monday, May, 1st. The company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.05. View Lion Biotechnologies' Earnings History.
Where is Lion Biotechnologies' stock going? Where will Lion Biotechnologies' stock price be in 2017?
9 brokers have issued twelve-month price objectives for Lion Biotechnologies' stock. Their forecasts range from $11.00 to $20.00. On average, they expect Lion Biotechnologies' stock price to reach $14.86 in the next year. View Analyst Ratings for Lion Biotechnologies.
What are analysts saying about Lion Biotechnologies stock?
Here are some recent quotes from research analysts about Lion Biotechnologies stock:
- 1. Cowen and Company analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
- 2. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (8/3/2017)
- 3. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)
- 4. Jefferies Group LLC analysts commented, "LBIO reported 4Q16 financials and provided a pipeline update. LN-144 is on track with enrollment with data expected in 2017 at a medical congress. LBIO is also planning for add'l clinical trials in 2017 and has initiated head and neck indication with the cervical indication to initiate shortly. We think LBIO is making reasonable progress and look to the first LN-144 data readout for more details." (3/8/2017)
Who are some of Lion Biotechnologies' key competitors?
Some companies that are related to Lion Biotechnologies include Quality Systems (QSII), Athenex (ATNX), Editas Medicine (EDIT), Cardiovascular Systems (CSII), Pharmerica Corporation (PMC), K2M Group Holdings (KTWO), Intellia Therapeutics (NTLA), Amarin Corporation PLC (AMRN), Retrophin (RTRX), BeyondSpring (BYSI), Luminex Corporation (LMNX), ZIOPHARM Oncology (ZIOP), NeoGenomics (NEO), Eagle Pharmaceuticals (EGRX), REGENXBIO (RGNX), Orthofix International N.V. (OFIX), Intersect ENT (XENT) and Intra-Cellular Therapies (ITCI).
Who are Lion Biotechnologies' key executives?
Lion Biotechnologies' management team includes the folowing people:
- Wayne Rothbaum, Interim Chairman of the Board
- Maria Fardis Ph.D., President, Chief Executive Officer
- Gregory T. Schiffman, Chief Financial Officer
- James G. Bender Ph.D., Vice President
- Iain D Dukes, Director
- Ryan D. Maynard, Director
- Sanford J. Hillsberg J.D., Independent Director
- Merrill A. McPeak USAF, Independent Director
- Jay Venkatesan M.D., Independent Director
Who owns Lion Biotechnologies stock?
Lion Biotechnologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (8.26%), FMR LLC (4.55%), Victory Capital Management Inc. (4.15%), Broadfin Capital LLC (3.63%), Vanguard Group Inc. (3.52%) and Frazier Management LLC (3.49%). View Institutional Ownership Trends for Lion Biotechnologies.
Who bought Lion Biotechnologies stock? Who is buying Lion Biotechnologies stock?
Lion Biotechnologies' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Victory Capital Management Inc., Broadfin Capital LLC, Vanguard Group Inc., Frazier Management LLC, JPMorgan Chase & Co. and State Street Corp. View Insider Buying and Selling for Lion Biotechnologies.
How do I buy Lion Biotechnologies stock?
Shares of Lion Biotechnologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lion Biotechnologies' stock price today?
MarketBeat Community Rating for Lion Biotechnologies (NASDAQ IOVA)MarketBeat's community ratings are surveys of what our community members think about Lion Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Lion Biotechnologies stock can currently be purchased for approximately $7.70.
Consensus Ratings for Lion Biotechnologies (NASDAQ:IOVA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||9 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$14.86 (92.95% upside)|
Analysts' Ratings History for Lion Biotechnologies (NASDAQ:IOVA)
(Data available from 9/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/13/2017||HC Wainwright||Reiterated Rating||Buy||$16.00||High|
|9/7/2017||Chardan Capital||Reiterated Rating||Buy||High|
|9/11/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$13.00||Low|
|9/5/2017||Jefferies Group LLC||Reiterated Rating||Buy||$11.00||High|
|8/16/2017||Cowen and Company||Reiterated Rating||Buy||Medium|
|5/18/2017||FBR & Co||Reiterated Rating||Buy||High|
|5/10/2017||Rodman & Renshaw||Initiated Coverage||Buy -> Buy||$13.00||Low|
|3/17/2017||Wells Fargo & Company||Initiated Coverage||Outperform -> Outperform||High|
|3/8/2017||Roth Capital||Set Price Target||Buy||$14.00||Low|
|6/6/2016||SunTrust Banks, Inc.||Downgrade||Buy -> Neutral||$37.00 -> $30.50||N/A|
|12/3/2015||Piper Jaffray Companies||Reiterated Rating||Buy||$21.00||N/A|
Earnings History for Lion Biotechnologies (NASDAQ:IOVA)Earnings History by Quarter for Lion Biotechnologies (NASDAQ IOVA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Lion Biotechnologies (NASDAQ:IOVA)
Current Year EPS Consensus Estimate: $-1.42 EPS
Next Year EPS Consensus Estimate: $-1.47 EPS
Dividend History for Lion Biotechnologies (NASDAQ:IOVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lion Biotechnologies (NASDAQ:IOVA)
Insider Ownership Percentage: 13.20%Insider Trades by Quarter for Lion Biotechnologies (NASDAQ:IOVA)
Institutional Ownership Percentage: 76.00%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/25/2016||Sanford Hillsberg||Director||Sell||54,000||$8.95||$483,300.00|| |
|8/22/2016||Sanford Hillsberg||Director||Sell||54,000||$9.11||$491,940.00|| |
|9/8/2015||Sanford Hillsberg||Director||Sell||32,500||$6.99||$227,175.00|| |
|5/6/2015||Sanford Hillsberg||Director||Sell||50,000||$10.00||$500,000.00|| |
|11/5/2013||Manish Singh||CEO||Buy||125,000||$2.00||$250,000.00|| |
Headline Trends for Lion Biotechnologies (NASDAQ:IOVA)
Latest Headlines for Lion Biotechnologies (NASDAQ:IOVA)
|Lion Biotechnologies, Inc. (IOVA) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - September 24 at 4:34 AM
| Analysts Expect Lion Biotechnologies, Inc. (IOVA) to Post -$0.35 EPS|
www.americanbankingnews.com - September 23 at 2:32 PM
|Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock|
finance.yahoo.com - September 20 at 9:24 PM
|Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock|
finance.yahoo.com - September 19 at 8:01 PM
|Lion Equity Partners Completes Acquisition of Vivabox USA from Sodexo|
www.businesswire.com - September 18 at 7:25 PM
|Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer|
finance.yahoo.com - September 14 at 6:31 AM
|Lion Biotechnologies' (IOVA) "Buy" Rating Reaffirmed at Chardan Capital|
www.americanbankingnews.com - September 13 at 7:18 PM
|Lion Biotechnologies, Inc. (IOVA) Earns "Buy" Rating from HC Wainwright|
www.americanbankingnews.com - September 13 at 8:04 AM
|Lion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - September 11 at 8:58 PM
|Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management|
finance.yahoo.com - September 11 at 8:40 PM
|Head-To-Head Review: Digiliti Money (DGLT) vs. Lion Biotechnologies (IOVA)|
www.americanbankingnews.com - September 8 at 12:30 PM
|Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center|
finance.yahoo.com - September 7 at 8:16 PM
|Iovance Biotherapeutics to Present at Two Upcoming September Conferences|
finance.yahoo.com - September 5 at 4:43 PM
|Zacks: Brokerages Expect Lion Biotechnologies, Inc. (IOVA) to Post -$0.35 Earnings Per Share|
www.americanbankingnews.com - September 4 at 6:20 PM
|InVitae Corp (NVTA) vs. Lion Biotechnologies (IOVA) Head-To-Head Analysis|
www.americanbankingnews.com - September 3 at 6:40 PM
|Chardan Capital Reaffirms "Buy" Rating for Lion Biotechnologies, Inc. (IOVA)|
www.americanbankingnews.com - September 1 at 12:56 PM
|Lion Biotechnologies, Inc. (IOVA) Given "Buy" Rating at HC Wainwright|
www.americanbankingnews.com - August 31 at 10:04 PM
|Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications|
finance.yahoo.com - August 31 at 7:58 PM
|Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma|
finance.yahoo.com - August 31 at 7:58 PM
|Lion Biotechnologies, Inc. (IOVA) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - August 30 at 4:30 AM
|Digiliti Money (DGLT) vs. Lion Biotechnologies (IOVA) Head to Head Contrast|
www.americanbankingnews.com - August 23 at 10:22 PM
|Head-To-Head Contrast: InVitae Corp (NVTA) versus Lion Biotechnologies (IOVA)|
www.americanbankingnews.com - August 20 at 4:22 PM
|Lion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target by Oppenheimer Holdings, Inc. Analysts|
www.americanbankingnews.com - August 19 at 11:32 PM
|Lion Biotechnologies (IOVA) and InVitae Corp (NVTA) Head-To-Head Survey|
www.americanbankingnews.com - August 18 at 2:26 PM
|Iovance Biotherapeutics Inc (IOVA) PT Set at $16.00 by HC Wainwright|
www.americanbankingnews.com - August 16 at 8:26 PM
|Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer|
finance.yahoo.com - August 16 at 4:43 PM
|Iovance Biotherapeutics Inc (IOVA) Stock Rating Reaffirmed by Cowen and Company|
www.americanbankingnews.com - August 16 at 3:12 PM
|Lion Biotechnologies (IOVA) & Veracyte (VCYT) Critical Analysis|
www.americanbankingnews.com - August 13 at 8:10 PM
|Head to Head Comparison: Lion Biotechnologies (IOVA) vs. Digiliti Money (DGLT)|
www.americanbankingnews.com - August 11 at 12:14 AM
|Analyzing Lion Biotechnologies (IOVA) and Veracyte (VCYT)|
www.americanbankingnews.com - August 9 at 10:50 PM
|Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer|
finance.yahoo.com - August 8 at 7:36 PM
|Lion Biotechnologies, Inc. (IOVA) Now Covered by Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - August 6 at 8:28 PM
|Lion Biotechnologies, Inc. (IOVA) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - August 5 at 7:09 AM
|Lion Biotechnologies, Inc. (NASDAQ:IOVA) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - August 3 at 11:38 PM
|Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 1 at 8:35 PM
|Lion Biotechnologies reports 2Q loss|
finance.yahoo.com - August 1 at 8:35 PM
|Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017|
finance.yahoo.com - July 25 at 8:17 PM
|Lion Biotechnologies (NASDAQ:IOVA) versus Veracyte (VCYT) Head to Head Comparison|
www.americanbankingnews.com - July 21 at 12:07 AM
|Lion Biotechnologies, Inc. (NASDAQ:IOVA) Upgraded by Zacks Investment Research to "Buy"|
www.americanbankingnews.com - July 19 at 12:52 AM
|Lion Biotechnologies, Inc. (NASDAQ:IOVA) Expected to Announce Earnings of -$0.34 Per Share|
www.americanbankingnews.com - July 5 at 10:16 PM
Lion Biotechnologies (IOVA) Chart for Sunday, September, 24, 2017